MedSci“临床科研中国行”全国巡回讲座--浙江省中医药大学

2012-06-15 MedSci MedSci原创

/* Style Definitions */ table.MsoNormalTable {mso-style-name:普通表格; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-priority:99; mso-style-parent:"";

MedSci“临床科研中国行”全国巡回讲座--浙江中医药大学站于2012年6月15日成功主办,本次讲座主题为《中医领域SCI论文选题与写作技巧》,由MedSci特邀嘉宾张博士主讲。讲座吸引了众多来自浙江中医药大学及其他院校的听众参与。

张博士自幼学习中医,硕士师承著名的中医针灸研究专家周逸平教授, 现为广州市政府国际顾问,同济大学医学院客座教授,同时兼任中国生物产业大奖|LSAC联合发起人兼秘书长、中国医药产业技术联盟专家委员会委员、全国18个生物类产业园区***/顾问,重点关注中医中药以及其政策和产业发展,生物产业发展趋势和动态,对生物医药领域的国内国际发展趋势与动态有较为深入的研究,在国际知名刊物Nature biotech(自然生物技术), BBRC(生物化学生物物理学研究通讯),cardiovascular research(心血管研究)等发表过多篇文章。  

张博士就中医领域中常见问题,如何从临床设计和创新性角度挖掘高质量的临床研究及规范的临床设计等方面介绍目前中国中医领域情况,传授撰写SCI论文选题技巧及写作技巧的宝贵经验,希望通过这次讲座提高中医界同仁高质量研究成果的转化。

MedSci将根据听者的反馈,继续组织并优化“临床科研中国行”全国巡回讲座的开展,为广大医务工作者的临床研究提供更多的信息和支持。 

在此感谢浙江中医药大学的大力支持!

由于听众超出预期,校方及时从舒适的会议厅转到了宽敞的教室,图片为讲座现场

张博士正在正在演讲

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2080691, encodeId=1f48208069160, content=<a href='/topic/show?id=7f664e84367' target=_blank style='color:#2F92EE;'>#巡回讲座#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47843, encryptionId=7f664e84367, topicName=巡回讲座)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c805395, createdName=ycmayy, createdTime=Wed Mar 27 09:00:00 CST 2013, time=2013-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738328, encodeId=80d91e3832820, content=<a href='/topic/show?id=f97a22012c2' target=_blank style='color:#2F92EE;'>#中国行#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22012, encryptionId=f97a22012c2, topicName=中国行)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3bb34418773, createdName=124987cdm37暂无昵称, createdTime=Mon Jan 07 14:00:00 CST 2013, time=2013-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747964, encodeId=d3df1e479646c, content=<a href='/topic/show?id=253e2935931' target=_blank style='color:#2F92EE;'>#全国巡回#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29359, encryptionId=253e2935931, topicName=全国巡回)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f89a35986479, createdName=w363522461, createdTime=Sat Jul 14 02:00:00 CST 2012, time=2012-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408594, encodeId=a6b21408594fa, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Jun 16 15:00:00 CST 2012, time=2012-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605745, encodeId=874b1605e4500, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jun 16 15:00:00 CST 2012, time=2012-06-16, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2080691, encodeId=1f48208069160, content=<a href='/topic/show?id=7f664e84367' target=_blank style='color:#2F92EE;'>#巡回讲座#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47843, encryptionId=7f664e84367, topicName=巡回讲座)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c805395, createdName=ycmayy, createdTime=Wed Mar 27 09:00:00 CST 2013, time=2013-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738328, encodeId=80d91e3832820, content=<a href='/topic/show?id=f97a22012c2' target=_blank style='color:#2F92EE;'>#中国行#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22012, encryptionId=f97a22012c2, topicName=中国行)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3bb34418773, createdName=124987cdm37暂无昵称, createdTime=Mon Jan 07 14:00:00 CST 2013, time=2013-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747964, encodeId=d3df1e479646c, content=<a href='/topic/show?id=253e2935931' target=_blank style='color:#2F92EE;'>#全国巡回#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29359, encryptionId=253e2935931, topicName=全国巡回)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f89a35986479, createdName=w363522461, createdTime=Sat Jul 14 02:00:00 CST 2012, time=2012-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408594, encodeId=a6b21408594fa, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Jun 16 15:00:00 CST 2012, time=2012-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605745, encodeId=874b1605e4500, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jun 16 15:00:00 CST 2012, time=2012-06-16, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2080691, encodeId=1f48208069160, content=<a href='/topic/show?id=7f664e84367' target=_blank style='color:#2F92EE;'>#巡回讲座#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47843, encryptionId=7f664e84367, topicName=巡回讲座)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c805395, createdName=ycmayy, createdTime=Wed Mar 27 09:00:00 CST 2013, time=2013-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738328, encodeId=80d91e3832820, content=<a href='/topic/show?id=f97a22012c2' target=_blank style='color:#2F92EE;'>#中国行#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22012, encryptionId=f97a22012c2, topicName=中国行)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3bb34418773, createdName=124987cdm37暂无昵称, createdTime=Mon Jan 07 14:00:00 CST 2013, time=2013-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747964, encodeId=d3df1e479646c, content=<a href='/topic/show?id=253e2935931' target=_blank style='color:#2F92EE;'>#全国巡回#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29359, encryptionId=253e2935931, topicName=全国巡回)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f89a35986479, createdName=w363522461, createdTime=Sat Jul 14 02:00:00 CST 2012, time=2012-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408594, encodeId=a6b21408594fa, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Jun 16 15:00:00 CST 2012, time=2012-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605745, encodeId=874b1605e4500, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jun 16 15:00:00 CST 2012, time=2012-06-16, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2080691, encodeId=1f48208069160, content=<a href='/topic/show?id=7f664e84367' target=_blank style='color:#2F92EE;'>#巡回讲座#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47843, encryptionId=7f664e84367, topicName=巡回讲座)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c805395, createdName=ycmayy, createdTime=Wed Mar 27 09:00:00 CST 2013, time=2013-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738328, encodeId=80d91e3832820, content=<a href='/topic/show?id=f97a22012c2' target=_blank style='color:#2F92EE;'>#中国行#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22012, encryptionId=f97a22012c2, topicName=中国行)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3bb34418773, createdName=124987cdm37暂无昵称, createdTime=Mon Jan 07 14:00:00 CST 2013, time=2013-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747964, encodeId=d3df1e479646c, content=<a href='/topic/show?id=253e2935931' target=_blank style='color:#2F92EE;'>#全国巡回#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29359, encryptionId=253e2935931, topicName=全国巡回)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f89a35986479, createdName=w363522461, createdTime=Sat Jul 14 02:00:00 CST 2012, time=2012-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408594, encodeId=a6b21408594fa, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Jun 16 15:00:00 CST 2012, time=2012-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605745, encodeId=874b1605e4500, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jun 16 15:00:00 CST 2012, time=2012-06-16, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2080691, encodeId=1f48208069160, content=<a href='/topic/show?id=7f664e84367' target=_blank style='color:#2F92EE;'>#巡回讲座#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47843, encryptionId=7f664e84367, topicName=巡回讲座)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c805395, createdName=ycmayy, createdTime=Wed Mar 27 09:00:00 CST 2013, time=2013-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738328, encodeId=80d91e3832820, content=<a href='/topic/show?id=f97a22012c2' target=_blank style='color:#2F92EE;'>#中国行#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22012, encryptionId=f97a22012c2, topicName=中国行)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c3bb34418773, createdName=124987cdm37暂无昵称, createdTime=Mon Jan 07 14:00:00 CST 2013, time=2013-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747964, encodeId=d3df1e479646c, content=<a href='/topic/show?id=253e2935931' target=_blank style='color:#2F92EE;'>#全国巡回#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29359, encryptionId=253e2935931, topicName=全国巡回)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f89a35986479, createdName=w363522461, createdTime=Sat Jul 14 02:00:00 CST 2012, time=2012-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408594, encodeId=a6b21408594fa, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Jun 16 15:00:00 CST 2012, time=2012-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605745, encodeId=874b1605e4500, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jun 16 15:00:00 CST 2012, time=2012-06-16, status=1, ipAttribution=)]

相关资讯

MedSci在2012细胞治疗技术研讨会上发表主题演讲

     受第2012细胞治疗技术研讨会邀请,MedSci在会议上发表题为“细胞治疗中的C2B2C——高质量临床研究设计与成果转化”主题演讲,受到广泛关注。本次会议由中国医师协会主办,广州军区广州总医院联合主办,生物谷承办,于2012年6月1-2日在广州召开,会议吸引了来自全国各地包括港台地区的600余位业内人士出席。    

预告:MedSci 2012“临床科研中国行”全国巡回讲座——福州站、杭州站

/* Style Definitions */ table.MsoNormalTable {mso-style-name:普通表格; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-priority:99; mso-style-parent:"";

MedSci“临床科研中国行”全国巡回讲座--广州市第一人民医院

MedSci“临床科研中国行”全国巡回讲座广州市第一人民医院于2012年6月6日成功主办,本次讲座主题为《临床资料如何转化成SCI文章》及《SCI论文发表支持与期刊选择技巧》,由MedSci高级学术顾问张博士、资深编辑朱博士分别主讲。张博士从临床设计入手,重点剖析临床研究创新点的挖掘及如何规范临床研究过程;朱博士结合中国学者在临床研究过程中常见的问题,就科研成果SCI文章的结构性写作部分与广大师生

MedSci“临床科研中国行”全国巡回讲座--广州军区广州总医院

MedSci“临床科研中国行”全国巡回讲座--广州军区广州总医院于2012年6月4日成功主办,本次讲座主题为《临床资料如何转化成SCI文章》及《SCI论文发表支持与期刊选择技巧》,由MedSci高级学术顾问张博士、资深编辑朱博士分别主讲。讲座吸引了众多来自广州军区广州总医院及其他院校的听众参与。 张博士从临床设计入手,重点剖析临床研究创新点的挖掘及如何规范临床研究过程,层次分明,现场气氛热烈且

预告:MedSci 2012“临床科研中国行”全国巡回讲座——广州站

MedSci作为专业科研与临床学术服务平台,致力于临床科研教育培训与医学学术服务指导,全面提升中国医学科研学术水平,全面对接中国与国际最新研究成果。 MedSci自2009年开始,推出“临床科研中国行”公益活动,围绕“SCI论文选题、写作与发表,高级医学统计与数据挖掘,循证医学与荟萃分析,国家自然科学基金申请辅导”四大主题,展开全国公益巡回授课;历经三年,讲座场次已近三百场,足迹遍布上海、天津、北

MedSci“临床科研中国行”全国巡回讲座--福建省立医院

MedSci“临床科研中国行”全国巡回讲座--福建省立医院于2012年6月14日成功主办,本次讲座主题为《临床研究设计与创新点寻找》及《临床研究资料收集、整理与数据统计和挖掘方法》,由MedSci高级学术顾问张博士、资深编辑朱博士分别主讲。讲座吸引了众多来自福建省立医院及其他院校的听众参与。  张博士从临床设计入手,重点剖析临床研究创新点的挖掘及如何通过规范的临床设计,发表高质量临床成